CG Inbites "Aselex-Pregabalin Combination Therapy Obtains US Patent"

CG Inbites announced on the 15th that it has obtained a U.S. patent for the combination therapy of 'Aselex (active ingredient Formacoxib) and Pregabalin' being developed as a treatment for neuropathic pain.

CG Inbites CI. [Image provided by CG Inbites]

The patent is titled "Pharmaceutical compositions for pain treatment comprising Formacoxib and Pregabalin." The main content of this patent is a method of treating pain by administering Formacoxib and Pregabalin at a weight ratio of 1:75 to 1:300.

Aselex is a drug used to treat chronic inflammation and pain, and the company explains that it can also suppress neuropathic pain to some extent. Chronic inflammation is known to cause neuropathic pain and chronic diseases.

Pregabalin, developed by Pfizer in the U.S., is a drug that specifically suppresses neuropathic pain. The company expects a synergistic effect with a lower dose when combined with Aselex.

Through this patent, CG Inbites has secured exclusive rights in the U.S. not only for the Formacoxib and Pregabalin combination drug obtained in April but also for the Formacoxib-Pregabalin combination therapy. The global market size for Pregabalin reached $800 million (approximately 1.06 trillion KRW) as of last year.

A CG Inbites representative said, "It is significant that we have secured multiple exclusive rights in the world's largest market, the U.S., not only for the Pregabalin combination drug but also for the combination therapy."

This content was produced with the assistance of AI translation services.